StreetInsider.com News Articles

Form 4 Twist Bioscience Corp For: Oct 09 Filed by: Laponis Adam

Tue, 13 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261013/27181118.html

Twist Bioscience (TWST) PT Raised to $190 at TD Cowen

Tue, 13 Oct 2026 09:39:22 -0400

TD Cowen analyst Brendan Smith raised the price target on Twist Bioscience (NASDAQ: TWST) to $190.00 (from $115.00) while maintaining a rating.

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

Investing.com -- The Federal Trade Commission and seven states are seeking to hold Martin Shkreli in contempt of court, alleging that the former pharmaceutical executive violated a lifetime ban on participating in the drug industry.

The motion, as described in the draft, centers on Shkreli’s alleged trading in pharmaceutical stocks and online commentary about biotech investments. Regulators contend that his activities violate a 2022 court order barring him from the pharmaceutical industry.

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

FTC seeks contempt finding against Martin Shkreli for alleged pharma ban violation

Tue, 13 Oct 2026 08:54:03 -0400

According to the allegations, Shkreli traded shares in at least 60 pharmaceutical companies and used livestreams on YouTube, X and Reddit to discuss trading strategies and short-selling campaigns. In

Twist Bioscience (TWST) PT Raised to $205 at Canaccord

Mon, 12 Oct 2026 06:38:16 -0400

Canaccord analyst Kyle Mikson raised the price target on Twist Bioscience (NASDAQ: TWST) to $205.00 (from $120.00) while maintaining a Buy rating.

Form 144 Twist Bioscience Corp Filed by: Laponis Adam

Fri, 09 Oct 2026 15:13:00 -0400

si-local-file:///var/storage/secattach/20261009/27171244.html

Twist Bioscience (TWST) PT Raised to $187 at Baird

Thu, 08 Oct 2026 07:24:00 -0400

Baird analyst Catherine Schulte raised the price target on Twist Bioscience (NASDAQ: TWST) to $187.00 (from $148.00) while maintaining a Outperform rating.

Jefferies Starts Twist Bioscience (TWST) at Hold

Thu, 08 Oct 2026 03:20:57 -0400

Jefferies analyst Matthew Stanton initiates coverage on Twist Bioscience (NASDAQ: TWST) with a Hold rating and a price target of $150.00.

The analyst comments: “TWST is a synthetic biology company that manufactures synthetic DNA and DNA-based products using proprietary, silicon-based DNA synthesis platform serving $10B+ TAM (growing +DD). Speed, scale and price drive differentiation that underpins share gains, penetration runway ahead. AIDD adoption adds incremental tailwind (orders growing triple digits). Premium valuation (~16x '28E revs), sets a high bar and embeds a lot of future success. Initiate at Hold, $150 PT.

TWST participates in $13B+ addressable markets today, including DNA Synthesis &

Jefferies Starts Twist Bioscience (TWST) at Hold

Thu, 08 Oct 2026 03:20:57 -0400

Jefferies analyst Matthew Stanton initiates coverage on Twist Bioscience (NASDAQ: TWST) with a Hold rating and a price target of $150.00.

TWST participates in $13B+ addressable markets today, including DNA Synthesis &

Form 4 Twist Bioscience Corp For: Oct 05 Filed by: Leproust Emily M.

Wed, 07 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261007/27161248.html

Increasing unusual call option volume: AZ TWST PENG DNA BMNU LEVI AGI CTVA ANNX WOOF KC STZ

Wed, 07 Oct 2026 10:20:25 -0400

Increasing unusual call option volume: AZ TWST PENG DNA BMNU LEVI AGI CTVA ANNX WOOF KC STZ

Twist Bioscience (TWST) PT Raised to $215 at Barclays

Wed, 07 Oct 2026 03:52:38 -0400

Barclays analyst Luke Sergott raised the price target on Twist Bioscience (NASDAQ: TWST) to $215.00 (from $112.00) while maintaining a Overweight rating.

Form 144 Twist Bioscience Corp Filed by: Leproust Emily M.

Mon, 05 Oct 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20261005/27149381.html

Form 4 Twist Bioscience Corp For: Oct 02 Filed by: Laponis Adam

Mon, 05 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261005/27148734.html

Form 4 Twist Bioscience Corp For: Oct 02 Filed by: WERNER ROBERT F.